By Don Dion:
Immune Design Corp (Pending:IMDZ), a clinical-stage immunotherapy firm, focused on the development of cancer treatments, plans to raise $60.5 million in its upcoming IPO.The Seattle, Washington-based firm will offer 4.7 million shares at an expected price range of $12-$14 per share. If the IPO can reach the midpoint of that range at $13 per share, IMDZ will command a market value of $221 million.
Fasting for three days can regenerate the entire immune system, even in the elderly, scientists have found in a breakthrough described as “remarkable.”
Although fasting diets have been criticized by nutritionists, research suggests that starving the body kick-starts stem cells into producing more white blood cells, which fight off infection.
At least five major drug companies, including Bristol-Myers Squibb, Merck and Roche, are developing immunotherapy drugs that work by unleashing the body's immune system to enable it to recognize and attack cancer cells.
By Michael Becker:As highlighted in our prior articles, growing evidence indicates that the field of cancer immunotherapy, broadly defined as including passive immunization, active immunization, and immunostimulation, is coming of age. More than 40 unique active cancer immunotherapies are currently being tested in over 60 clinical trials, with nearly a dozen readouts from randomized Phase 2 or Phase 3 trials expected during the next 12-months.